斑块炎症与颈动脉血运重建未获益患者卒中复发的关联
该研究汇总3项前瞻性队列的个体数据,纳入135例近期前循环缺血性卒中/TIA且颈动脉狭窄程度在内膜切除术试验中未明确获益的患者,评估SCAIL评分(含狭窄程度和PET炎症)对90天同侧缺血性卒中复发的识别能力。结果显示SCAIL评分每增加1分,复发风险比为2.16(95%CI 1.32-3.53;p=0.002),评分≥2对复发敏感性为100%。作者认为SCAIL评分可改善此类患者早期复发识别,需随机试验验证。
要点
- 在血运重建未获益的亚组中,SCAIL评分0-1、2-3、4-5分的90天复发率分别为0.0%、15.1%、26.7%(p=0.04)。
- SCAIL评分每增加1分,同侧复发卒中调整HR为2.16(95%CI 1.32-3.53;p=0.002)。
- SCAIL评分≥2对复发性卒中的敏感性为100%。
核心结论
- SCAIL评分改善了在内膜切除术试验中未获益亚组患者的早期复发性卒中识别。
- 需要随机试验检验狭窄-炎症联合策略能否改善当前获益不确定时颈动脉血运重建的选择。
研究设计与样本
- 研究为3项前瞻性队列研究(DUCASS,2008-2011;BIOVASC,2014-2018;Barcelona Plaque Study,2015-2018)的个体参与者数据汇总分析。
- 纳入标准为近期非严重(改良Rankin量表评分≤3)前循环缺血性卒中/TIA且同侧颈动脉轻度狭窄(<50%);或同侧中度狭窄(50%-69%)合并女性、年龄<65岁、糖尿病、TIA或至血运重建延迟>14天中至少1项;或单眼视力丧失。
- 患者接受配准的颈动脉18F-氟脱氧葡萄糖PET/CT血管造影(自纳入起≤7天内)。
- 共纳入135例患者,主要结局为90天同侧缺血性卒中,采用多变量Cox回归建模。
主要发现
- 所有患者入院时开始最佳现代药物治疗,62例(45.9%)接受颈动脉血运重建(其中36例在最初14天内,26例在14天后)。
- 90天时18例(13.3%)患者发生至少1次卒中复发。
- 复发风险随SCAIL评分升高而逐步增加:评分0-1分患者为0.0%,评分2-3分为15.1%,评分4-5分为26.7%(p=0.04)。
- 调整年龄、吸烟、高血压、糖尿病、颈动脉血运重建、抗血小板药和他汀后,SCAIL评分每增加1分,同侧复发性卒中的风险比为2.16(95%CI 1.32-3.53;p=0.002)。
- SCAIL评分≥2对复发的敏感性为100%。
关键数值与推荐
- SCAIL评分0-1分、2-3分、4-5分的90天同侧缺血性卒中复发率分别为0.0%、15.1%、26.7%(p=0.04)。
- SCAIL评分每增加1分,调整后同侧复发性卒中HR为2.16(95%CI 1.32-3.53;p=0.002)。
- SCAIL评分≥2对复发性卒中的敏感性为100%。
临床怎么用
- 作者认为SCAIL评分可改善内膜切除术试验未获益亚组患者的早期复发性卒中识别。
- 作者建议需随机试验检验狭窄-炎症联合策略能否改善当前获益不确定时颈动脉血运重建的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In pooled analyses of endarterectomy trials for symptomatic carotid stenosis, several subgroups experienced no net benefit from revascularization. The validated symptomatic carotid atheroma inflammation lumen-stenosis (SCAIL) score includes stenosis severity and inflammation measured by PET and improves the identification of patients with recurrent stroke compared with lumen-stenosis alone. We investigated whether the SCAIL score improves the identification of recurrent stroke in subgroups with uncertain benefit from revascularization in endarterectomy trials. METHODS: We did an individual-participant data pooled analysis of 3 prospective cohort studies (Dublin Carotid Atherosclerosis Study [DUCASS], 2008-2011; Biomarkers and Imaging of Vulnerable Atherosclerosis in Symptomatic Carotid Artery Disease [BIOVASC], 2014-2018; Barcelona Plaque Study, 2015-2018). Eligible patients had a recent nonsevere (modified Rankin Scale score ≤3) anterior circulation ischemic stroke/TIA and ipsilateral mild carotid stenosis (<50%); ipsilateral moderate carotid stenosis (50%-69%) plus at least 1 of female sex, age <65 years, diabetes mellitus, TIA, or delay >14 days to revascularization; or monocular loss of vision. Patients underwent coregistered carotid 18F-fluorodeoxyglucosePET/CT angiography (≤7 days from inclusion). The primary outcome was 90-day ipsilateral ischemic stroke. Multivariable Cox regression modeling was performed. RESULTS: We included 135 patients. All patients started optimal modern-era medical treatment at admission, and 62 (45.9%) underwent carotid revascularization (36 within the first 14 days and 26 beyond). At 90 days, 18 (13.3%) patients had experienced at least 1 stroke recurrence. The risk of recurrence increased progressively according to the SCAIL score (0.0% in patients scoring 0-1, 15.1% scoring 2-3, and 26.7% scoring 4-5; p = 0.04). The adjusted (age, smoking, hypertension, diabetes, carotid revascularization, antiplatelets and statins) hazard ratio for ipsilateral recurrent stroke per 1-point SCAIL increase was 2.16 (95% CI 1.32-3.53; p = 0.002). A score ≥2 had a sensitivity of 100% for recurrence. DISCUSSION: The SCAIL score improved the identification of early recurrent stroke in subgroups who did not experience benefit in endarterectomy trials. Randomized trials are needed to test whether a combined stenosis-inflammation strategy will improve selection for carotid revascularization when benefit is currently uncertain. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, in patients with recent anterior circulation ischemic stroke who do not benefit from carotid revascularization, the SCAIL score accurately distinguishes those at risk for recurrent ipsilateral ischemic stroke.
引用
- Camps-Renom P, McCabe J, Martí-Fàbregas J, et al. Association of Plaque Inflammation With Stroke Recurrence in Patients With Unproven Benefit From Carotid Revascularization. Neurology. 2022. PMID: 35418461. doi:10.1212/WNL.0000000000200525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。